





Multiple Disease Sites

UCI 13-49 Open-Label Dose-Escalation Trial to Evaluate the Safety, PK, and PD of Daily Oral MGCD265 Administered Without Interruption to Subjects with Advanced Malignancies **(Ou)**

UCI 16-96 A Phase I Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors **(Ou)**

ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) (Larynx, Lip, Oral Cavity & Pharynx) **(Seery)**

UCI 17-50 ** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors **(Ou)**

UCI 17-58** Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas **(Pinter-Brown)**

Correlative

UCI 14-36 A Correlative Study to Examine Cancer Molecular Alterations Using a Blood Based Assay **(Seery)**
UCI 14-25 Plasma Exosome Concentration in Cancer Patients Undergoing Treatment **(Nelson)**
UCI 16-01 (PAINT Cancer)-Pathway Analyses for Individualized Network Therapeutics for Cancer **(Nelson)**